Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials
<p>Abstract</p> <p>Background</p> <p>Because of the subjective nature of Restless Legs Syndrome (RLS) symptoms and the impact of these symptoms on sleep, patient-reported outcomes (PROs) play a prominent role as study endpoints in clinical trials investigating RLS treat...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-04-01
|
Series: | BMC Neurology |
Online Access: | http://www.biomedcentral.com/1471-2377/11/48 |
id |
doaj-26d6c9d2fb4b42069218481e46083a0d |
---|---|
record_format |
Article |
spelling |
doaj-26d6c9d2fb4b42069218481e46083a0d2020-11-24T23:27:17ZengBMCBMC Neurology1471-23772011-04-011114810.1186/1471-2377-11-48Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trialsBharmal MurtuzaBhanegaonkar AbhijeetCanafax Daniel MCalloway Michael<p>Abstract</p> <p>Background</p> <p>Because of the subjective nature of Restless Legs Syndrome (RLS) symptoms and the impact of these symptoms on sleep, patient-reported outcomes (PROs) play a prominent role as study endpoints in clinical trials investigating RLS treatments. The objective of this study was to validate a new measure, the Post Sleep Questionnaire (PSQ), to assess sleep dysfunction in subjects with moderate-to-severe RLS symptoms.</p> <p>Methods</p> <p>Pooled data were analyzed from two 12-week, randomized, placebo-controlled trials of gabapentin enacarbil (N = 540). At baseline and Week 12, subjects completed the PSQ and other validated health surveys: IRLS Rating Scale, Clinical Global Impression of Improvement (CGI-I), Profile of Mood States (POMS), Medical Outcomes Study Scale-Sleep (MOS-Sleep), and RLS-Quality of Life (RLSQoL). Pooled data were used <it>post hoc </it>to examine the convergent, divergent, known-group validity and the responsiveness of the PSQ.</p> <p>Results</p> <p>Convergent validity was demonstrated by significant correlations between baseline PSQ items and total scores of IRLS, POMS, RLSQoL, and the MOS-Sleep Scale (p ≤ 0.007 each). Divergent validity was demonstrated through the lack of significant correlations between PSQ items and demographic characteristics. Correlations (p < 0.0001) between RLS severity groups and PSQ items demonstrated known-group validity. Mean changes in investigator- and subject-rated CGI-I scores for each PSQ item (p < 0.0001) demonstrated the PSQ's responsiveness to patient change as reported by their care provider.</p> <p>Conclusions</p> <p>Although these analyses were potentially limited by the use of clinical trial data and not prospective data from a study conducted solely for validation purposes, the PSQ demonstrated robust psychometric properties and is a valid instrument for assessing sleep and sleep improvements in subjects with moderate-to-severe RLS symptoms.</p> <p>Trial Registration</p> <p>This study analyzed data from two registered trials, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00298623">NCT00298623</a> and <a href="http://www.clinicaltrials.gov/ct2/show/NCT00365352">NCT00365352</a>.</p> http://www.biomedcentral.com/1471-2377/11/48 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Bharmal Murtuza Bhanegaonkar Abhijeet Canafax Daniel M Calloway Michael |
spellingShingle |
Bharmal Murtuza Bhanegaonkar Abhijeet Canafax Daniel M Calloway Michael Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials BMC Neurology |
author_facet |
Bharmal Murtuza Bhanegaonkar Abhijeet Canafax Daniel M Calloway Michael |
author_sort |
Bharmal Murtuza |
title |
Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials |
title_short |
Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials |
title_full |
Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials |
title_fullStr |
Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials |
title_full_unstemmed |
Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials |
title_sort |
validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials |
publisher |
BMC |
series |
BMC Neurology |
issn |
1471-2377 |
publishDate |
2011-04-01 |
description |
<p>Abstract</p> <p>Background</p> <p>Because of the subjective nature of Restless Legs Syndrome (RLS) symptoms and the impact of these symptoms on sleep, patient-reported outcomes (PROs) play a prominent role as study endpoints in clinical trials investigating RLS treatments. The objective of this study was to validate a new measure, the Post Sleep Questionnaire (PSQ), to assess sleep dysfunction in subjects with moderate-to-severe RLS symptoms.</p> <p>Methods</p> <p>Pooled data were analyzed from two 12-week, randomized, placebo-controlled trials of gabapentin enacarbil (N = 540). At baseline and Week 12, subjects completed the PSQ and other validated health surveys: IRLS Rating Scale, Clinical Global Impression of Improvement (CGI-I), Profile of Mood States (POMS), Medical Outcomes Study Scale-Sleep (MOS-Sleep), and RLS-Quality of Life (RLSQoL). Pooled data were used <it>post hoc </it>to examine the convergent, divergent, known-group validity and the responsiveness of the PSQ.</p> <p>Results</p> <p>Convergent validity was demonstrated by significant correlations between baseline PSQ items and total scores of IRLS, POMS, RLSQoL, and the MOS-Sleep Scale (p ≤ 0.007 each). Divergent validity was demonstrated through the lack of significant correlations between PSQ items and demographic characteristics. Correlations (p < 0.0001) between RLS severity groups and PSQ items demonstrated known-group validity. Mean changes in investigator- and subject-rated CGI-I scores for each PSQ item (p < 0.0001) demonstrated the PSQ's responsiveness to patient change as reported by their care provider.</p> <p>Conclusions</p> <p>Although these analyses were potentially limited by the use of clinical trial data and not prospective data from a study conducted solely for validation purposes, the PSQ demonstrated robust psychometric properties and is a valid instrument for assessing sleep and sleep improvements in subjects with moderate-to-severe RLS symptoms.</p> <p>Trial Registration</p> <p>This study analyzed data from two registered trials, <a href="http://www.clinicaltrials.gov/ct2/show/NCT00298623">NCT00298623</a> and <a href="http://www.clinicaltrials.gov/ct2/show/NCT00365352">NCT00365352</a>.</p> |
url |
http://www.biomedcentral.com/1471-2377/11/48 |
work_keys_str_mv |
AT bharmalmurtuza validationofthepostsleepquestionnaireforassessingsubjectswithrestlesslegssyndromeresultsfromtwodoubleblindmulticenterplacebocontrolledclinicaltrials AT bhanegaonkarabhijeet validationofthepostsleepquestionnaireforassessingsubjectswithrestlesslegssyndromeresultsfromtwodoubleblindmulticenterplacebocontrolledclinicaltrials AT canafaxdanielm validationofthepostsleepquestionnaireforassessingsubjectswithrestlesslegssyndromeresultsfromtwodoubleblindmulticenterplacebocontrolledclinicaltrials AT callowaymichael validationofthepostsleepquestionnaireforassessingsubjectswithrestlesslegssyndromeresultsfromtwodoubleblindmulticenterplacebocontrolledclinicaltrials |
_version_ |
1725552632516313088 |